Lind Global Fund II Takes 9.99% Stake in Cyclacel Pharma
Ticker: BGMSP · Form: SC 13G · Filed: Jan 4, 2024 · CIK: 1130166
Complexity: simple
Sentiment: bullish
Topics: institutional-investment, stake-acquisition, pharmaceuticals
TL;DR
**Lind Global Fund II just bought nearly 10% of Cyclacel Pharma, a bullish sign!**
AI Summary
Lind Global Fund II LP, a New York-based investment firm, reported acquiring 1,000,000 shares of Cyclacel Pharmaceuticals, Inc. common stock, representing 9.99% of the company's outstanding shares, as of December 26, 2023. This significant stake, valued at $0.001 par value per share, indicates a notable vote of confidence from an institutional investor in the pharmaceutical company. For current or prospective shareholders, this could signal potential future growth or a belief that Cyclacel's stock is undervalued, potentially attracting more investor interest.
Why It Matters
A large institutional investor taking a significant stake often signals confidence in a company's future, which can positively influence other investors and potentially boost stock price.
Risk Assessment
Risk Level: low — This filing indicates an institutional investment, generally seen as a positive development with low inherent risk.
Analyst Insight
A smart investor would research Cyclacel Pharmaceuticals, Inc.'s fundamentals and recent news to understand why Lind Global Fund II LP took such a significant position, potentially indicating an undervalued asset or positive future prospects.
Key Numbers
- 9.99% — Percentage of Class Outstanding (The total percentage of Cyclacel Pharmaceuticals, Inc. common stock owned by Lind Global Fund II LP.)
- 1,000,000 — Shares Beneficially Owned (The total number of common shares of Cyclacel Pharmaceuticals, Inc. beneficially owned by Lind Global Fund II LP.)
- December 26, 2023 — Date of Event (The date when the event requiring this Schedule 13G filing occurred.)
- 23254L801 — CUSIP Number (Unique identification number for Cyclacel Pharmaceuticals, Inc. common stock.)
Key Players & Entities
- Lind Global Fund II LP (company) — the investment firm acquiring shares
- Cyclacel Pharmaceuticals, Inc. (company) — the subject company whose shares were acquired
- JEFF EASTON (person) — a group member associated with the filing
- LIND GLOBAL PARTNERS II LLC (company) — a group member associated with the filing
- 03 Life Sciences (company) — an organization name associated with the subject company
- $0.001 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- Cyclacel Pharmaceuticals, Inc. stock price may see increased investor interest due to this significant institutional stake. (Cyclacel Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
- Lind Global Fund II LP may seek to engage with Cyclacel management regarding strategic direction or operational improvements. (Lind Global Fund II LP) — low confidence, target: Q2 2024
FAQ
Who filed this SC 13G statement?
The SC 13G statement was filed by Lind Global Fund II LP, located at 444 Madison Avenue, 41st Floor, New York, NY 10022.
What company's shares are the subject of this filing?
The subject company is Cyclacel Pharmaceuticals, Inc., with its business address at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
What percentage of Cyclacel Pharmaceuticals, Inc.'s common stock does Lind Global Fund II LP now beneficially own?
Lind Global Fund II LP beneficially owns 9.99% of the common stock of Cyclacel Pharmaceuticals, Inc.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 26, 2023.
What is the par value per share of Cyclacel Pharmaceuticals, Inc. common stock?
The common stock of Cyclacel Pharmaceuticals, Inc. has a par value of $0.001 per share.
Filing Stats: 1,451 words · 6 min read · ~5 pages · Grade level 11.1 · Accepted 2024-01-04 16:30:14
Key Financial Figures
- $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie
Filing Documents
- sch13g.htm (SC 13G) — 67KB
- exhibit99-1.htm (EX-99.1) — 7KB
- 0000929638-24-000024.txt ( ) — 76KB
Ownership of Five Percent or Less of a Class
Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .
Ownership of More than Five Percent on Behalf of Another Person
Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits Exhibit 99.1 Joint Filing Agreement by and among the Reporting Persons. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 4, 2024 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC its General Partner By: /s/ Jeff Easton Name: Jeff Easton Title: Managing Member LIND GLOBAL PARTNERS II LLC By: /s/ Jeff Easton Name: Jeff Easton Title: Managing Member JEFF EASTON By: /s/ Jeff Easton